Perspectives in antisense therapeutics

被引：68

作者：

Agrawal, S ^{[1
]}

Iyer, RP ^{[1
]}

机构：

[1] Hybridon Inc, Cambridge, MA 02139 USA

来源：

PHARMACOLOGY & THERAPEUTICS | 1997年 / 76卷 / 1-3期

关键词：

oligonucleoside phosphorothioates; mixed-backbone oligonucleotides; pharmacokinetics; oral bioavailability; toxicology;

D O I：

10.1016/S0163-7258(97)00108-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Modulation of gene expression using oligonucleotides (oligos) is currently an area of intense activity, both from therapeutic, as well as research perspectives. To develop oligos as therapeutic agents, in addition to demonstrable biological activity, in vico metabolic stability, tissue disposition and pharmacokinetics are important considerations. Oligodeoxynucleoside phosphorothioates are the first-generation antisense analogs that have been studied extensively, and are in clinical trials against a number of disease indications. In an effort to improve the antisense properties of these compounds, mixed-backbone oligos incorporating different chemical modifications have been synthesized and evaluated for antisense activity, The present review will provide an overview of the pharmacokinetics and toxicology following intravenous, intraperitoneal, subcutaneous and oral administration of mixed-backbone oligos as second-generation antisense therapeutics. (C) 1997 Elsevier Science Inc.

引用

页码：151 / 160

页数：10

共 35 条

[21] In vivo suppression of the renal Na+/P-i cotransporter by antisense oligonucleotides
Oberbauer, R
Schreiner, GF
Biber, J
Murer, H
Meyer, TW
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (10) : 4903 - 4906
[22] TRANSPORT OF PHOSPHOROTHIOATE OLIGONUCLEOTIDES IN KIDNEY - IMPLICATIONS FOR MOLECULAR THERAPY
RAPPAPORT, J
HANSS, B
KOPP, JB
COPELAND, TD
BRUGGEMAN, LA
COFFMAN, TM
KLOTMAN, PE
[J]. KIDNEY INTERNATIONAL, 1995, 47 (05) : 1462 - 1469
[23] SANDS H, 1994, MOL PHARMACOL, V45, P932
[24] INHIBITION OF ACQUIRED IMMUNODEFICIENCY SYNDROME VIRUS BY OLIGODEOXYNUCLEOSIDE METHYLPHOSPHONATES
SARIN, PS
AGRAWAL, S
CIVEIRA, MP
GOODCHILD, J
IKEUCHI, T
ZAMECNIK, PC
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (20) : 7448 - 7451
[25] IN-VIVO TOXICOLOGICAL EFFECTS OF REL-A ANTISENSE PHOSPHOROTHIOATES IN CD-1 MICE
SARMIENTO, UM
PEREZ, JR
BECKER, JM
NARAYANAN, R
[J]. ANTISENSE RESEARCH AND DEVELOPMENT, 1994, 4 (02): : 99 - 107
[26] RENAL DISPOSITION CHARACTERISTICS OF OLIGONUCLEOTIDES MODIFIED AT TERMINAL LINKAGES IN THE PERFUSED RAT-KIDNEY
SAWAI, K
MIYAO, T
TAKAKURA, Y
HASHIDA, M
[J]. ANTISENSE RESEARCH AND DEVELOPMENT, 1995, 5 (04): : 279 - 287
[27] REVIEW OF IN-VIVO PHARMACOKINETICS AND TOXICOLOGY OF PHOSPHOROTHIOATE OLIGONUCLEOTIDES
SRINIVASAN, SK
IVERSEN, P
[J]. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1995, 9 (02) : 129 - 137
[28] EFFECT OF RNA SECONDARY STRUCTURE AND MODIFIED BASES ON THE INHIBITION OF TRYPANOSOMATID PROTEIN-SYNTHESIS IN CELL-FREE-EXTRACTS BY ANTISENSE OLIGODEOXYNUCLEOTIDES
VERSPIEREN, P
LOREAU, N
THUONG, NT
SHIRE, D
TOULME, JJ
[J]. NUCLEIC ACIDS RESEARCH, 1990, 18 (16) : 4711 - 4717
[29] WICKSTROM E, 1991, PROSPECTS ANTISENSE
[30] INHIBITION OF ROUS-SARCOMA VIRUS-REPLICATION AND CELL TRANSFORMATION BY A SPECIFIC OLIGODEOXYNUCLEOTIDE
ZAMECNIK, PC
STEPHENSON, ML
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1978, 75 (01) : 280 - 284

← 1 2 3 4 →